Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Chio

Showing results (31-40 of 77) with videos related to

Pageof 8
Sort By:
JAMA Neurology|March 16, 2026
Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical TrialMerit Cudkowicz, Vivian E Drory, Adriano Chio, et al.
Muscle & Nerve|June 6, 2025
Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)Jeffrey Rothstein, Angela Genge, Shari De Silva, et al.
Neurology|January 23, 2024
Cognitive and Behavioral Features of Patients With Amyotrophic Lateral Sclerosis Who Are Carriers of the <i>TARDBP</i> Pathogenic VariantCristina Moglia, Andrea Calvo, Antonio Canosa, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 29, 2021
GBA variants influence cognitive status in amyotrophic lateral sclerosisAntonio Canosa, Maurizio Grassano, Cristina Moglia, et al.
Neurology. Genetics|September 15, 2022
Phenotype Analysis of Fused in Sarcoma Mutations in Amyotrophic Lateral SclerosisMaurizio Grassano, Giorgia Brodini, Giovanni De Marco, et al.
BMJ Open|June 2, 2019
Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS)Jessica Mandrioli, Valeria Crippa, Cristina Cereda, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|February 27, 2010
Guidelines for preclinical animal research in ALS/MND: A consensus meetingAlbert C Ludolph, Caterina Bendotti, Eran Blaugrund, et al.
Human Molecular Genetics|February 4, 2017
C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of PtenMatthew J Stopford, Adrian Higginbottom, Guillaume M Hautbergue, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 25, 2022
Exploring the phenotype of Italian patients with ALS with intermediate <i>ATXN2</i> polyQ repeatsAdriano Chio, Cristina Moglia, Antonio Canosa, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 10, 2020
TRICALS: creating a highway toward a cureRuben P A van Eijk, Tessa Kliest, Christopher J McDermott, et al.
Pageof 8

Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
JAMA Neurology|March 16, 2026
Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical TrialMerit Cudkowicz, Vivian E Drory, Adriano Chio, et al.
Muscle & Nerve|June 6, 2025
Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)Jeffrey Rothstein, Angela Genge, Shari De Silva, et al.
Neurology|January 23, 2024
Cognitive and Behavioral Features of Patients With Amyotrophic Lateral Sclerosis Who Are Carriers of the <i>TARDBP</i> Pathogenic VariantCristina Moglia, Andrea Calvo, Antonio Canosa, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 29, 2021
GBA variants influence cognitive status in amyotrophic lateral sclerosisAntonio Canosa, Maurizio Grassano, Cristina Moglia, et al.
Neurology. Genetics|September 15, 2022
Phenotype Analysis of Fused in Sarcoma Mutations in Amyotrophic Lateral SclerosisMaurizio Grassano, Giorgia Brodini, Giovanni De Marco, et al.
BMJ Open|June 2, 2019
Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS)Jessica Mandrioli, Valeria Crippa, Cristina Cereda, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|February 27, 2010
Guidelines for preclinical animal research in ALS/MND: A consensus meetingAlbert C Ludolph, Caterina Bendotti, Eran Blaugrund, et al.
Human Molecular Genetics|February 4, 2017
C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of PtenMatthew J Stopford, Adrian Higginbottom, Guillaume M Hautbergue, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 25, 2022
Exploring the phenotype of Italian patients with ALS with intermediate <i>ATXN2</i> polyQ repeatsAdriano Chio, Cristina Moglia, Antonio Canosa, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 10, 2020
TRICALS: creating a highway toward a cureRuben P A van Eijk, Tessa Kliest, Christopher J McDermott, et al.
Pageof 8